Objective: To investigate associations between prostate cancer and sexually transmitted diseases (STDs), prostatitis, benign prostatic hyperplasia (BPH), and vasectomy in a population-based case-control study in Wayne County, Michigan, among African American and white men aged 50-74 years.
Introduction
Prostate cancer is the most commonly diagnosed noncutaneous cancer and the second leading cause of cancer deaths in men in the United States [1] . It is estimated that one in every five American men will be affected by this disease [2] . Racial variations in incidence and mortality rates of prostate cancer are striking: African American men have the highest age-adjusted incidence rate of prostate cancer in the world (185.7 per 100,000), markedly higher than that of U.S. white men (110 per 100,000), with a mortality rate more than twice that of white men [3, 4] .
Despite the considerable disease burden, relatively little is known about risk factors for prostate cancer or reasons for racial and ethnic differentials in risk. Epidemiologic studies of numerous putative risk factors for prostate cancer (including diet, body mass index (BMI), smoking, alcohol consumption, and physical activity) have been conducted, with inconsistent findings. The only well established risk factors for prostate cancer include age, race, and a family history of prostate cancer [5] .
Recent studies have explored the contribution of sexually transmitted diseases (STDs) to the development of prostate malignancy. Specific STD agents have been associated inconsistently with prostate cancer, with positive associations reported with gonorrhea [6, 7] , syphilis [7] , and human papilloma virus (HPV) [8, 9] . Recent national data suggest that African Americans have substantially higher rates of STDs than other racial and ethnic groups in the United States [10, 11] . The possible influence of STDs has been suggested as a partial explanation for the higher rates of prostate cancer among African Americans [12] , however, this relationship has not been well characterized.
Associations between urogenital conditions other than STDs and prostate cancer have also been studied, with inconsistent results. Prostatitis, a commonly occurring inflammation or infection of the prostate, is an important cause of morbidity in adult males [13] [14] [15] [16] . Most previous case-control studies examining prostatitis and prostate cancer did not report significant associations [17] [18] [19] [20] [21] ; however, Honda et al. reported an increased risk (OR ¼ 2.2; 95% CI: 1.2, 4.3) [22] . Benign prostatic hyperplasia (BPH) is another highly prevalent condition among middle-aged and elderly men [23] , but findings from epidemiologic studies of the association between BPH and prostate cancer have been inconsistent [24] [25] [26] [27] .
Men who have undergone vasectomy have been shown to have a moderately higher risk of prostate cancer in some studies [28] [29] [30] [31] [32] [33] , while other studies have reported no association [17, 20, 22, [34] [35] [36] [37] [38] [39] . Because the prevalence of male sterilization (approximately 11%) has remained relatively stable in the U.S. since 1982 [40] and, worldwide, an estimated 42-60 million couples rely on vasectomy for contraception [38] , any association of vasectomy with prostate cancer would be of importance.
This report is based on men in the metropolitan Detroit area who participated in a population-based case-control study of occupational risk factors for prostate cancer. The primary focus of this case-control study was to examine associations between occupational exposures and prostate cancer; the secondary analysis presented here considers associations of prostate cancer with a history of STD and other urogenital conditions, including prostatitis, BPH, and vasectomy.
Materials and methods

Case and control ascertainment
Cases were identified through the Metropolitan Detroit Cancer Surveillance System (MDCSS), a populationbased cancer registry established in the 1950s, and a founding member of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program since 1973. Because of the large volume of prostate cancer cases reported in the MDCSS registry (exceeding sample size requirements), a random sample of half of all malignant prostate cancer cases diagnosed between April 1, 1996 and March 30, 1998 were identified. Eligible cases included those with histologically confirmed adenocarcinoma of the prostate (ICD-O topography code C61.9 [41] ), aged 50-74 years, residing in Wayne County at the time of diagnosis, who spoke English and had a working telephone number. Wayne County, which includes the city of Detroit, was selected because of the high proportion of African American residents (over 40%). The physician of record for each case was sent a letter explaining the nature of the study and inquiring whether there was any medical reason not to contact the case. Each potential case not excluded by his physician was sent a letter explaining the nature of the study, and trained interviewers attempted to contact these cases within one week of the introductory letter. If the subject agreed to participate, arrangements were made for an in-person interview.
Controls were initially identified through a randomdigit dialing (RDD) telephone sample of Wayne County residents, aged 50-74 years, who spoke English and had a working telephone number. Controls were selected by stratified random sampling using Waksberg's two-stage RDD method [42] and were frequency matched to the cases by race (white, African American, and other) and age (in five-year intervals). To include sufficient numbers of controls in older age groups, a random sample of Medicare recipients aged 65-74 years with working telephone numbers obtained from a Health Care Financing Administration (HCFA) listing was also used. Potential controls were sent introductory letters similar to those sent to potential cases requesting participation. The study protocol and consent form were approved by the Wayne State University Human Investigation Committee and all subjects provided written informed consent prior to the interview.
Interview
Trained interviewers asked cases and controls about demographics, medical history, family medical history, physical activity, lifestyle factors, household exposures, and occupational history using a structured questionnaire. Within the medical history section, subjects were asked to self-report their past history of four specific STDs (gonorrhea, syphilis, chancroid, genital herpes) or ''other'' STDs, and urogenital conditions other than STDs, including prostatitis, BPH, and vasectomy. Subjects were also asked to report their past history of transurethral resection of the prostate (TURP), a common surgical treatment for BPH. Exposures were assessed for the period before a specified reference date, which was the date of diagnosis for cases and the date of study entry for controls.
Cases were compared to controls to determine whether the two groups differed according to matching variables, subject characteristics (including marital status, education, current BMI, cigarette use prior to reference date, average weekly number of alcoholic drinks in the previous year, and family history of prostate cancer), and risk factors of interest. A positive family history of prostate cancer (in first degree relatives only) was defined as self-reported history of prostate cancer in the subject's father and/or brother(s). History of specific STDs was based on self-report; in addition, a positive history of ''any STD'' was defined by self-reported history of at least one of the four specific STDs or ''other'' STD. For cases, tumor stage and grade were ascertained through linkage with the MDCSS database. Tumor stage was categorized as localized, regional (regional direct extension; regional lymph nodes; regional direct extension and regional lymph nodes; or regional, not otherwise specified), distant, or unknown. MDCSS records tumor grade as well differentiated (Gleason score 2-4), moderately differentiated (Gleason score 5-7), poorly differentiated (Gleason score 8-10), or unknown.
Statistical analysis
Comparisons of categorical variables between cases and controls were made using two-tailed v 2 tests in the entire study sample and within African American and white men (stratified). p-Values <0.05 were considered statistically significant. Unconditional logistic regression analyses were conducted to explore relationships between urogenital conditions and prostate cancer by estimating odds ratios (OR) and 95% confidence intervals (CI). These analyses were first conducted in the entire sample and then were repeated after stratifying by race to examine potential interactions between race and each urogenital condition. Additionally, interaction terms between race and each urogenital condition were added to the appropriate multivariable models and assessed for statistical significance. Adjustments for age (as a continuous variable), education level, family history of prostate cancer (in first degree relatives only) and, where appropriate, race were included in all logistic regression models, because these variables were associated with either prostate cancer or the risk factor of interest. The potential for confounding and effect modification by other subject characteristics was also investigated, including marital status, current BMI, cigarette use prior to the reference date, and average weekly number of alcoholic drinks in the previous year; however, because the effects were not statistically significant, these variables were not included in the multivariable models.
We examined associations between BPH, TURP and prostate cancer because TURP may increase the detection rate for prostate cancer. Because of the potential for reporting bias for topics of a sensitive nature, analyses for the associations between prostate cancer and history of STD, prostatitis and BPH were repeated after excluding participants who had another individual present during their interview. Data analyses were performed using SAS version 8.2 (SAS Institute, Cary, NC, USA) [43] .
Results
Study sample
Of the 1287 men with prostate cancer who were eligible to be cases, 730 (56.7%) completed the interview ( Of the 1457 total potentially eligible controls, 686 (47.1%) were interviewed (Table 1) . Of the 771 individuals not interviewed, 29 (3.8%) died before contact could be made, 396 (51.4%) refused to participate, 45 (5.8%) were too ill or hard of hearing, and 301 (39.0%) were unable to be contacted. Of the 686 individuals who were interviewed, 2 (0.3%) did not complete the interview, 46 (6.7%) were excluded because of a prior diagnosis of prostate cancer, and 34 (5.0%) were excluded because they identified ''other'' race or did not provide race information. Analyses were thus limited to the 604 African American and white controls who completed an interview. Of the participating controls, 46% were selected through RDD and 54% through HCFA. Telephone numbers were not available for 185 (28.4%) of the 651 randomly selected HCFA controls; 63 (34.1%) of these were contacted door-todoor and the remaining 122 (66.0%) were excluded. The average time interval between date of study entry and interview of controls was 4.5 months (range: 0-35.8; standard deviation: 4.8).
Subject characteristics
Overall, 700 eligible prostate cancer cases diagnosed between April 1996 and March 1998 and 604 controls were included in the analyses (Table 2 ). Cases and controls were similar with respect to marital status, current BMI, smoking history, average weekly number of alcoholic drinks in the previous year, and the presence of anyone else during the interview. Overall, a greater proportion of cases was older (p ¼ 0.04), African American (p ¼ 0.005), had attained less education (p ¼ 0.03), and had a family history of prostate cancer in first degree relatives (p ¼ 0.0004) compared to controls. A smaller proportion of cases had a history of vasectomy (p ¼ 0.007) compared to controls. Among the 610 African American subjects, there were no significant differences between cases and controls for any of the characteristics presented in Table 2 . Among the 694 white subjects, a greater proportion of cases was older (p ¼ 0.04) and had a family history of prostate cancer in first degree relatives (p ¼ 0.0012) compared to controls. Chi-squared p < 0.05 among all cases and controls combined (does not include don't know or not asked). Because most men with a history of STD reported only one episode of infection (with the exception of gonorrhea), frequency of infection is only presented for any STD and for gonorrhea. Both overall and within African Americans or whites, men with one, two, or three or more episodes of any STD did not demonstrate higher odds of prostate cancer compared to those without a history of any STD, after adjusting for covariates. Similarly, no significant associations were observed between men with one, two, or three or more episodes of gonorrhea compared to those without a history of gonorrhea, either overall or within African Americans or whites.
We analyzed history of any STD by tumor stage and grade among cases, but did not find significant differences in the distribution of STD history by early (localized) versus advanced (regional plus distant) stage tumors (excluding unknown, p ¼ 0.49) or by grade (excluding unknown, p ¼ 0.28).
Associations of prostatitis and BPH with prostate cancer
After adjusting for age, race, education, and family history of prostate cancer in first degree relatives, the odds of prostate cancer among men with a history of prostatitis were nearly twice that of men without a history of prostatitis in the entire sample (OR ¼ 1.8, 95% CI: 1.1, 2.9) ( Table 3) . After stratifying by race, the odds of prostate cancer among men with a history of prostatitis were twice the odds of those without a history of prostatitis in African American men (OR ¼ 2.2, 95% CI: 1.1, 4.6). There was no evidence for interaction between race and history of prostatitis (p for interaction term ¼ 0.57).
The odds of prostate cancer among men with a history of BPH were over twice the odds of men without a history of BPH (OR ¼ 2.4, 95% CI: 1.8, 3.3), after adjusting for age, race, education, and family history of prostate cancer in first degree relatives (Table 3) . After stratifying by race, the odds of prostate cancer among men with a history of BPH were more than twice the odds of those without a history of BPH in both African American (OR ¼ 2.7, 95% CI: 1.6, 4.4) and white (OR ¼ 2.3, 95% CI: 1.5, 3.4) men. There was no evidence for interaction between race and history of BPH (p for interaction term ¼ 0.84).
Men in this study with a history of BPH were over six times as likely to have undergone TURP compared to those without a history of BPH (OR ¼ 6.4, 95% CI: 4.0, 10.1) (data not shown). Among the 342 men with a history of BPH there was no significant association between TURP and prostate cancer (OR ¼ 0.9, 95% CI: 0.5, 1.6) For a considerable proportion of cases (22.9%) and controls (22.5%), at least one other individual was present during their interview. The analyses were repeated after excluding 296 subjects who had someone else present during their interview and 51 subjects for whom this information was not recorded by the interviewer. For all odds ratios presented in Table 3 , the estimates did not differ by more than 10%, and the directions of the effects were unchanged (data not shown).
Associations of vasectomy with prostate cancer
Odds ratios for history of vasectomy, age at vasectomy, and interval since vasectomy are shown in Table 4 . Because only six African American subjects (three cases, three controls) reported a history of vasectomy, these analyses combined African American and white subjects. All odds ratios were adjusted for age, race, education, and family history of prostate cancer in first degree relatives. A history of vasectomy was reported by 72 cases (10.3%) and 92 controls (15.2%). There was no significant association between vasectomy history and prostate cancer (OR ¼ 1.0, 95% CI: 0.7, 1.5), after adjusting for covariates in the model. Age at vasectomy was not significantly associated with prostate cancer with the exception that men who had a vasectomy between ages 35 and 39 had lower odds of prostate cancer as compared to men without a history of vasectomy (OR ¼ 0.6, 95% CI: 0.4, 0.9). Interval since vasectomy was not significantly associated with prostate cancer. No trend of increasing prostate cancer odds with successively younger ages at or longer intervals since vasectomy was observed.
Discussion
In this study we examined associations between prostate cancer and STDs, prostatitis, BPH, and vasectomy. A strength of the study was the inclusion of a large number of African American prostate cancer cases and population-based controls, which enabled us to assess the effects of potential risk factors both in the entire study sample and among African American and white men. A number of studies have examined STD history in relation to risk of prostate cancer, reporting mixed findings. Research has focused primarily on gonorrhea, syphilis, chlamydia, herpes simplex virus (HSV), and HPV. Hayes et al. conducted one of the largest population-based case-control investigations of STDs and prostate cancer to date, and found that cases were more likely to report a history of gonorrhea or syphilis (OR ¼ 1.6, 95% CI: 1.2, 2.1), to show serological evidence of syphilis (OR ¼ 1.8, 95% CI: 1.0, 3.5), and to have a higher frequency of gonorrhea episodes (p for trend ¼ 0.009) [7] . Another population-based case-control study reported a borderline significant increased risk of prostate cancer among men with prior gonorrhea infection (OR ¼ 1.5, 95% CI: 1.02, 2.18) [6] , whereas no evidence for gonorrhea as a risk factor for prostate cancer was found in a hospital-based case-control study conducted among men in Greece [44] . Two populationbased case-control studies examining the relationship between chlamydia infection and prostate cancer did not report significant associations [6, 8] . HPV, in particular, has generated interest due to its strong association with other genitourinary cancers; associations of HPV with prostate cancer have been reported in some studies [8, 9] but not others [6, [45] [46] [47] .
In the late 1980s Ross et al. conducted case-control studies of prostate cancer risk factors among African American and white men in California to elucidate reasons for the differential in prostate cancer risk in these two racial groups [20] . The authors found an elevated risk of prostate cancer in both African American (relative risk (RR) ¼ 1.7) and white (RR ¼ 2.3) men with a history of STD, with the RR achieving statistical significance in African American men. Significant differences in sexual activity factors, including frequency of sexual intercourse, age at first sexual intercourse, and number of spouse's pregnancies, were also proposed as possible explanations for the increased risk of prostate cancer among African American men. More recently, it has been suggested that the higher incidence rate of prostate cancer in African Americans may be partially due to a greater prevalence of oncogenic viral DNA in prostatic tissues [47] .
Our results do not indicate an important role for sexually transmitted agents in the etiology of prostate cancer; however, there are several potential limitations that should be considered in the interpretation our findings. It is conceivable that stronger associations between STD history and prostate cancer may exist among men with an advanced stage of disease at diagnosis. However, the majority of cases in our study had localized tumors (79.1%), so we were not able to conduct a complete analysis of the men with advanced tumors. We did not have information on timing of infections; thus, if the relevant window of exposure is either earlier or later in life, our study may have attenuated the true associations between these infections and prostate cancer. We relied on self-report of past history of STD, which is difficult to validate and may be limited by a subject's ability to recognize asymptomatic infection or recall the event, reluctance to admit a stigmatic condition, or lack of awareness of a specific diagnosis made in the past. Moreover, information on STD history is subject to social desirability bias, that is, subjects may be inclined to provide answers they believe are more socially acceptable to others present at interview. To address the potential for bias in STD reporting, we repeated the analyses after excluding subjects who had someone else present during their interview. Though the absence of another person during the interview does not preclude misclassification of exposures with in-person interviews, it was useful to note that the associations between prostate cancer and history of STD, prostatitis and BPH were essentially unchanged after the exclusions.
The high non-participation rate (ratio of interviewed to total potentially eligible men) may limit the generalizability of the results obtained from the final study sample. We note that there is some evidence for different participation rates in our cases and controls by age and race. Although we adjusted for these variables in our analyses, nevertheless the adjustment may not completely account for this potential bias or other uncontrolled selection forces which may have affected our study findings. In order to enrich our study population with older controls, a random sample of Medicare recipients aged 65-74 years with working telephone numbers obtained from a HCFA listing was used in addition to RDD controls. We cannot exclude the potential for a selection bias if those HCFA controls with working telephone numbers that we were able to contact and interview somehow differed from potential controls without working telephone numbers. The interval between identification of cases through the rapid reporting system and date of interview was substantial, for several reasons. Our study population included older, urban men, a group that may be more difficult to reach for interviews. Additionally, obtaining physician consent prior to contacting cases for interview and errors in initial contact information obtained through the rapid reporting system contributed to delays in interviewing cases. Several measures to enhance the quality of the study were instituted, including the use of rapid reporting data updates and reverse telephone directories to correct errors in contact information.
Our study demonstrated that prostate cancer cases were nearly twice as likely to have a history of prostatitis compared to controls, and a similar, significant association was also evident in African American men. No interaction between race and history of prostatitis was observed. The observed positive association between prostatitis and prostate cancer in our study (OR ¼ 1.8, 95% CI: 1.1, 2.9) was consistent with results of a recent study by Roberts et al. (OR ¼ 1.7, 95% CI: 1.1, 2.6) [21] . A potential mechanism of carcinogenesis involving repeated tissue damage and regeneration in the presence of highly reactive oxygen and nitrogen species lends biological plausibility to the association between prostatitis and prostate cancer [48] . Our results could reflect either an etiological connection between prostatitis and prostate cancer or could reflect a detection bias; many men with elevated serum prostate-specific antigen levels undergo prostate biopsy for evaluation for possible prostate cancer; based on histological criteria, prostatitis is the most common noncancer diagnosis [49] . The epidemiological literature on the association between chronic prostatitis and risk of prostate cancer is limited, largely due to the difficulty in characterizing this clinical entity and the lack of a valid practical definition [50] . It is also unclear whether chronic inflammation influences prostate cancer initiation, promotion, or both processes [51] . In our study, we are not aware if men with prostatitis were diagnosed by a urologist or primary care physician, and there may be differences in the diagnostic approach used by these types of physicians [15] . Furthermore, self-reported prostatitis information was not adequate to determine whether the prostatitis episodes were acute or chronic, bacterial or nonbacterial, so we were limited to the broad classification of ''prostatitis'' as a covariate of interest for prostate cancer. There is some potential for misclassification of exposure status due to the lack of clear-cut diagnostic criteria and the overlap between symptoms of prostatitis and BPH. However, identifiable correlates of prostatitis do exist (such as age, severe lower urinary tract symptoms, high stress, and history of vasectomy and STD), and their inclusion in future studies should enhance recognition of this condition and help distinguish it from BPH. Using data from the Health Professionals Follow-Up Study, Collins et al. reported that men with a history of BPH had 7.7-fold greater odds (95% CI: 7.2, 8.3) of prostatitis compared to men without BPH history [15] . Studies that distinguish between acute bacterial, chronic bacterial, and nonbacterial prostatitis, though difficult and expensive to undertake, could enhance our understanding of the potential infectious and inflammatory roles for prostatitis in prostate cancer risk.
Our study also suggested that prostate cancer cases were more than twice as likely to have a past history of BPH, both overall (OR ¼ 2.4, 95% CI: 1.8, 3.3) and within African American (OR ¼ 2.7, 95% CI: 1.6, 4.4) and white (OR ¼ 2.3, 95% CI: 1.5, 3.4) men. No interaction between race and history of BPH was observed. As discussed above in relation to prostatitis, the observed association could be a result of referral bias or detection bias. Men seen by urologists may be screened more vigilantly and, thus, may be more likely to be diagnosed with another urological condition. Men who are diagnosed with BPH may be subject to additional medical care and may be more closely followed up for other prostate problems, including prostate cancer. TURP is a common surgical treatment for BPH and could explain the observed association between BPH and prostate cancer. Incidental detection of prostate cancer through TURP is thought to explain slightly less than ten percent of all detected cases [52] . In the current study, we did not find a significant association between TURP and prostate cancer among men with a history of BPH. A recent review of the epidemiologic literature found no relationship between BPH and prostatic adenocarcinomas arising in the peripheral zone and weak evidence between BPH and prostatic adenocarcinomas originating in the transition zone [53] ; a much more likely explanation for our findings is that BPH and prostate cancer share common predisposing factors.
Overall, we found no significant association between history of vasectomy and prostate cancer, with the exception that men who had a vasectomy between 35 and 39 years of age had decreased odds of prostate cancer (OR ¼ 0.6, 95% CI: 0.4, 0.9). Previous studies have suggested an elevated risk of prostate cancer among men who underwent vasectomies at younger ages, but the observed effects were not statistically significant [36, 39] . It would be expected that differential surveillance for and/or detection of prostate cancer among men who have undergone vasectomy would increase the odds of prostate cancer: men who have seen a urologist for a vasectomy may have subsequently been exposed to more digital rectal examinations or invasive procedures used to diagnose prostate cancer [54] . We were unable to examine associations of vasectomy with prostate cancer by race because only six African American men (1%) reported a history of vasectomy in this study; this is consistent with previously reported vasectomy rates of 1-2% among African Americans in the U.S. [40] . The underlying mechanisms by which this sterilization procedure could influence prostate carcinogenesis remain unclear, but commonly offered biological explanations include the potential for this surgery to alter endocrine function and plasma hormone levels [55] or a permanent reduction in prostatic secretions following vasectomy resulting in prolonged exposure of prostatic glands to carcinogenic factors present in prostatic fluid [31] . As prostate cancer is a hormonally-related cancer, it is biologically plausible that clinical syndromes that influence hormone levels may affect risk of prostate cancer [50] .
A body of evidence for an infectious component to prostate cancer development has begun to emerge; however, the inconsistent results of previously conducted studies suggest the need for additional research in this area. As the carcinogenic effects of chronic inflammation have been considered in organs including the liver, esophagus, large bowel, urinary bladder and gastric mucosa [13, 56] , the study of prostatitis in relation to prostate cancer could shed light on a potential inflammatory etiology of prostate cancer. Observed associations between BPH and prostate cancer may reflect common predisposing factors. Questions remain as to whether men with a history of prostatitis or BPH have an increased risk of prostate cancer, whether the observed association is due to some degree of recall bias, or whether these men simply undergo more vigilant prostate cancer screening; future studies should take into account screening patterns to examine the potential role of detection and recall bias. The lack of association between vasectomy and prostate cancer in this study should be assuring in light of the limited contraceptive options for men and the widespread practice of vasectomy throughout the world. Prevention efforts could be enhanced if inflammatory or infectious etiologies are found to be of importance in the subsequent development of prostate cancer.
